Millennium Management LLC Has $32.21 Million Stock Holdings in Cryoport, Inc. (NASDAQ:CYRX)

Millennium Management LLC lifted its holdings in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 11.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,139,869 shares of the company's stock after purchasing an additional 409,353 shares during the quarter. Millennium Management LLC owned approximately 8.38% of Cryoport worth $32,208,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of CYRX. Lazard Asset Management LLC acquired a new position in shares of Cryoport during the 4th quarter worth $51,000. Avanza Fonder AB acquired a new position in shares of Cryoport during the 4th quarter worth $64,000. Quarry LP acquired a new position in shares of Cryoport during the 4th quarter worth $69,000. Nebula Research & Development LLC increased its stake in shares of Cryoport by 21.6% during the 4th quarter. Nebula Research & Development LLC now owns 12,442 shares of the company's stock worth $97,000 after purchasing an additional 2,207 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of Cryoport by 135.5% during the 4th quarter. Russell Investments Group Ltd. now owns 12,875 shares of the company's stock worth $100,000 after purchasing an additional 7,407 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company's stock.

Insider Buying and Selling at Cryoport

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the sale, the chief executive officer now directly owns 765,399 shares of the company's stock, valued at $4,814,359.71. This represents a 0.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 19,830 shares of company stock valued at $118,353 in the last ninety days. Company insiders own 10.00% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Guggenheim restated a "buy" rating and set a $10.00 price target on shares of Cryoport in a research note on Wednesday, April 16th. UBS Group upped their price objective on shares of Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. Morgan Stanley decreased their price objective on shares of Cryoport from $8.00 to $7.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. Roth Mkm reaffirmed a "buy" rating and set a $15.00 price objective on shares of Cryoport in a report on Tuesday, April 1st. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price objective on shares of Cryoport in a report on Thursday, May 8th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $11.00.

Cryoport Stock Performance

Cryoport stock traded down $0.18 during mid-day trading on Friday, reaching $6.04. The company had a trading volume of 253,099 shares, compared to its average volume of 544,154. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. Cryoport, Inc. has a 52 week low of $4.58 and a 52 week high of $11.64. The company has a 50 day moving average of $5.93 and a 200-day moving average of $6.82. The firm has a market cap of $302.83 million, a price-to-earnings ratio of -1.79 and a beta of 1.92.

Cryoport (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The firm had revenue of $41.04 million during the quarter, compared to the consensus estimate of $56.19 million. On average, sell-side analysts expect that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.